Entrada Therapeutics Secures $255M Runway to Q3 2027 After ELEVATE-44 Cohort 1 Success
Entrada Therapeutics reported topline results from Cohort 1 of its ELEVATE-44-201 trial in Duchenne muscular dystrophy, with 6 mg/kg dosing delivering Time to Rise gains and no serious adverse events. It closed Q1 with $255 million cash, extending runway into Q3 2027, and expects ELEVATE-45-201 Cohort 1 data in mid-2026.
1. Financial Results and Cash Position
Entrada ended the first quarter with $255 million in cash, cash equivalents and marketable securities as of March 31, 2026, funding operations into the third quarter of 2027. The company hosted an investor webcast on May 7 to discuss these results and reaffirmed its financial runway for upcoming clinical programs.
2. ELEVATE-44-201 Cohort 1 Topline Results
The global Phase 1/2 multiple ascending dose study of ENTR-601-44 in ambulatory Duchenne muscular dystrophy patients amenable to exon 44 skipping showed that three 6 mg/kg doses produced statistically significant improvements in Time to Rise velocity. Adverse events were limited to mild or moderate severity, with no serious events or discontinuations and normal kidney function markers.
3. Upcoming Clinical Milestones
Entrada plans to report Cohort 1 data from its ELEVATE-45-201 trial in mid-2026 and deliver open-label and Cohort 2 (12 mg/kg) results for ELEVATE-44-201 by year-end 2026. The company is also pursuing regulatory authorizations and dosing for ENTR-601-50 and ENTR-601-51 studies, targeting exon 50 and exon 51 skipping populations respectively.